Serum lipid and lipoprotein concentrations treated and non-treated with statins in post-renal transplant patient (Tx)

Le résumé fourni par la source

Cardiovascular diseases (CVDs), including acute myocardial infarction, cardiac arrhytmias, heart failure and stroke have become the leading cause of mortality in renal transplant recipients, accounting for over 50% of deaths in these patients. The studies were performed in 20 renal transplant patients (Tx) (male and female) at the age between 21–60 years and the reference group. Tx patients were without an active inflammatory disease, liver disease, malignancy, or diabetes mellitus, and they were not smokers. Seventeen patients had hypertension. The causes of renal insufficiency in the post-renal transplant (Tx) patients were: 11 glomerulonephritis, 5 interstitial nephritis, 2 polycystic disease, 2 hypertensive nephrosclerosis. The post-renal transplant patients received cyclosporine A (CsA) + prednisone (n=13), tacrolimus + prednisone (n=7) and atrovastatine or simvastatine (n=10). They received a low dose of statins. Tx patients (n=20) were divided into 2 groups: Tx patients with (n=10) and without statins therapy (n=10). The present study examined clinical and routine laboratory parameters and lipids, lipoproteins and lipid and lipoproteins ratios in Tx patients treated and non-treated with statins. Lipids, lipoproteins, routine laboratory parameters were obtained in the serum after 14-hour overnight fasting. Routine laboratory parameters (the level of urea, uric acid, creatinine, total protein, albumin) and lipids and lipoproteins (apoA, apoB) were determined on Hitachi 902 analyzer, and hemoglobin using ADVIA analyser, Bayer. LDL-cholesterol (LDL-C) was calculated according to the Friedewald formula. Non-HDL-cholesterol (non-HDL-C) was calculated as total cholesterol (TC) minus HDL-C. The obtained results in Tx patients with statins therapy shows worse clinical and laboratory parameters. The results indicated that Tx patients with statins therapy had a significantly higher concentration of TG, non-HDL-C and TC/HDL-C, TG/HDL-C ratios, and a lower concentration of HDL-C, and apoAI/apoB, HDL-C/apoAI ratios than Tx patients without statins therapy. However, the concentrations TC, LDL-C and apoB were simile in both studied group. Moreover, in both concentrations of TG, non-HDL-C and TC/HDL-C, LDL-C/HDL-C, TG/HDL-C ratios were significantly increased, but HDL-C level and apoAI/apoB, HDL-C/apoAI ratios were decreased in comparison to the reference group. A variety of immunosuppressive therapies in Tx patients are seen to be one of the main factors that influence post-renal transplant abnormal lipid and lipoprotein profiles. The statins therapy demonstrate a favourable effect on the concentration of total cholesterol and LDL-cholesterol but a minor role in triglyceride and HDL-cholesterol levels. Statins can prevent progression of atherosclerosis and chronic allograft failure in Tx patients. However, future studies are required.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.